newsfilter
← Latest News
GlobeNewswire·

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen